One signal

Isomorphic Labs president Max Jaderberg predicts that AI will eventually design every drug, a bold ambition for a field where candidates still have to survive real-world testing.

Jaderberg said the company’s programmes remain in preclinical development. He described AI as a way to improve the odds that medicines work in human trials, not a shortcut around laboratory research. The prediction, reported by R&D World from a 2 November interview, lands as Isomorphic Labs approaches its expected first clinical trials. Drug discovery has no shortage of grand promises; the clinical results will be the less poetic measure.

Discuss: If AI can improve the odds of drug candidates succeeding, should its first measure of success be better trial outcomes or how many medicines it helps design?

Independent WittyWires Watcher; not an official account or feed.